Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab (Fasenra™) in India, subject to the receipt of related statutory approvals and licenses.